false--12-31Q22019000031015816324000000170490000001190000001220000000.480.960.551.100.500.5065000000006500000000357710352235771035220.01850.023500.02400.038750P24YP18Y344000000200000010000009845439791010308500 0000310158 2019-01-01 2019-06-30 0000310158 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0000310158 mrk:A1.875Notesdue2026Member 2019-01-01 2019-06-30 0000310158 mrk:A1.375Notesdue2036Member 2019-01-01 2019-06-30 0000310158 mrk:A0.500Notesdue2024Member 2019-01-01 2019-06-30 0000310158 mrk:A2.500Notesdue2034Member 2019-01-01 2019-06-30 0000310158 mrk:A1.125Notesdue2021Member 2019-01-01 2019-06-30 0000310158 2019-07-31 0000310158 2018-04-01 2018-06-30 0000310158 2018-01-01 2018-06-30 0000310158 2019-04-01 2019-06-30 0000310158 2019-06-30 0000310158 2018-12-31 0000310158 2017-12-31 0000310158 2018-06-30 0000310158 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000310158 mrk:AntelliqMember 2019-04-01 0000310158 mrk:ImmuneDesignMember 2019-04-30 0000310158 mrk:ViralyticsMember 2018-01-01 2018-06-30 0000310158 mrk:PelotonMember us-gaap:SubsequentEventMember 2019-07-01 2019-07-31 0000310158 mrk:PelotonMember us-gaap:SubsequentEventMember 2019-07-31 0000310158 mrk:ViralyticsMember 2018-06-01 2018-06-30 0000310158 mrk:ViralyticsMember 2018-06-30 0000310158 mrk:AntelliqMember 2019-04-01 2019-04-01 0000310158 mrk:AntelliqMember us-gaap:MeasurementInputDiscountRateMember 2019-04-01 0000310158 mrk:ImmuneDesignMember 2019-04-01 2019-04-30 0000310158 srt:MaximumMember 2019-04-01 2019-04-01 0000310158 srt:MinimumMember 2019-04-01 2019-04-01 0000310158 mrk:ViralyticsMember 2018-04-01 2018-06-30 0000310158 mrk:AstraZenecaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2019-04-01 2019-06-30 0000310158 mrk:AstraZenecaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2019-04-01 2019-06-30 0000310158 mrk:AstraZenecaMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2018-12-31 0000310158 mrk:AstraZenecaMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-06-30 0000310158 mrk:AstraZenecaMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-06-30 0000310158 mrk:AstraZenecaMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2018-12-31 0000310158 mrk:AstraZenecaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-06-30 0000310158 mrk:AstraZenecaMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2019-04-01 2019-06-30 0000310158 mrk:AstraZenecaMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2019-06-30 0000310158 mrk:AstraZenecaMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2019-06-30 0000310158 mrk:AstraZenecaMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2019-04-01 2019-06-30 0000310158 mrk:AstraZenecaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-06-30 0000310158 mrk:AstraZenecaMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2018-12-31 0000310158 mrk:AstraZenecaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2018-04-01 2018-06-30 0000310158 mrk:AstraZenecaMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-06-30 0000310158 mrk:AstraZenecaMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2019-06-30 0000310158 mrk:AstraZenecaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-06-30 0000310158 mrk:AstraZenecaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2018-04-01 2018-06-30 0000310158 mrk:AstraZenecaMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2018-04-01 2018-06-30 0000310158 mrk:AstraZenecaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-06-30 0000310158 mrk:AstraZenecaMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-06-30 0000310158 mrk:AstraZenecaMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2018-04-01 2018-06-30 0000310158 mrk:BayerAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-06-30 0000310158 mrk:BayerAGMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-06-30 0000310158 mrk:BayerAGMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-06-30 0000310158 mrk:BayerAGMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2018-04-01 2018-06-30 0000310158 mrk:BayerAGMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2018-04-01 2018-06-30 0000310158 mrk:BayerAGMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-06-30 0000310158 mrk:BayerAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-06-30 0000310158 mrk:BayerAGMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2018-04-01 2018-06-30 0000310158 mrk:BayerAGMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2019-04-01 2019-06-30 0000310158 mrk:BayerAGMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-06-30 0000310158 mrk:BayerAGMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2018-12-31 0000310158 mrk:BayerAGMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2019-04-01 2019-06-30 0000310158 mrk:BayerAGMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2019-06-30 0000310158 mrk:BayerAGMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2019-06-30 0000310158 mrk:BayerAGMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-06-30 0000310158 mrk:BayerAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2019-04-01 2019-06-30 0000310158 mrk:BayerAGMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2019-04-01 2019-06-30 0000310158 mrk:BayerAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2018-04-01 2018-06-30 0000310158 mrk:BayerAGMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2018-12-31 0000310158 mrk:BayerAGMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-06-30 0000310158 mrk:BayerAGMember mrk:AdempasMember 2018-04-01 2018-06-30 0000310158 mrk:EisaiMember mrk:SalesBasedMilestonesMember 2019-01-01 2019-06-30 0000310158 mrk:EisaiMember mrk:RegulatoryMilestonesMember 2019-01-01 2019-06-30 0000310158 mrk:AstraZenecaMember srt:ScenarioForecastMember 2019-12-01 2019-12-31 0000310158 mrk:EisaiMember srt:ScenarioForecastMember 2018-03-01 2021-03-31 0000310158 mrk:EisaiMember 2019-03-01 2019-03-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:RegulatoryMilestonesMember 2019-04-01 2019-04-30 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:SalesBasedMilestonesMember 2019-01-01 2019-06-30 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:SalesBasedMilestonesMember 2018-01-01 2018-12-31 0000310158 mrk:BayerAGMember mrk:SalesBasedMilestonesMember 2019-01-01 2019-06-30 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2018-01-01 2018-12-31 0000310158 mrk:LenvimaMember us-gaap:OtherNoncurrentAssetsMember 2019-06-30 0000310158 mrk:EisaiMember mrk:SalesBasedMilestonesMember 2018-03-01 2018-03-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:RegulatoryMilestonesMember 2019-01-01 2019-06-30 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:RegulatoryMilestonesMember 2019-06-01 2019-06-30 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:SalesBasedMilestonesMember 2019-03-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember 2019-04-01 2019-06-30 0000310158 mrk:AstraZenecaMember 2017-01-01 2017-12-31 0000310158 mrk:EisaiMember 2018-01-01 2018-03-31 0000310158 mrk:EisaiMember mrk:LenvimaMember 2019-01-01 2019-03-31 0000310158 mrk:AstraZenecaMember mrk:SalesBasedMilestonesMember 2019-01-01 2019-06-30 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:RegulatoryMilestonesMember 2018-01-01 2018-12-31 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:RegulatoryMilestonesMember 2018-01-01 2018-12-31 0000310158 mrk:AstraZenecaMember 2017-07-01 2017-07-31 0000310158 mrk:AstraZenecaMember 2017-12-01 2017-12-31 0000310158 mrk:AstraZenecaMember mrk:SalesBasedMilestonesMember 2017-07-01 2018-12-31 0000310158 mrk:AdempasMember us-gaap:OtherIntangibleAssetsMember 2019-06-30 0000310158 mrk:BayerAGMember mrk:SalesBasedMilestonesMember 2018-01-01 2018-03-31 0000310158 mrk:EisaiMember srt:ScenarioForecastMember 2020-03-01 2020-03-31 0000310158 mrk:EisaiMember srt:ScenarioForecastMember 2021-03-01 2021-03-31 0000310158 mrk:BayerAGMember mrk:SalesBasedMilestonesMember 2018-06-30 0000310158 mrk:LynparzaMember us-gaap:OtherNoncurrentAssetsMember 2019-06-30 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:SalesBasedMilestonesMember 2019-01-01 2019-03-31 0000310158 mrk:EisaiMember mrk:RegulatoryMilestonesMember 2018-03-01 2018-03-31 0000310158 mrk:BayerAGMember mrk:SalesBasedMilestonesMember 2018-04-01 2018-06-30 0000310158 mrk:AstraZenecaMember 2018-12-01 2018-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2019-06-30 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2019-04-01 2019-06-30 0000310158 mrk:EisaiMember 2018-03-01 2018-03-31 0000310158 mrk:EisaiMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2018-12-31 0000310158 mrk:EisaiMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2019-06-30 0000310158 mrk:EisaiMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2019-06-30 0000310158 mrk:EisaiMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-06-30 0000310158 mrk:EisaiMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2018-04-01 2018-06-30 0000310158 mrk:EisaiMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2019-04-01 2019-06-30 0000310158 mrk:EisaiMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-06-30 0000310158 mrk:EisaiMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2019-04-01 2019-06-30 0000310158 mrk:EisaiMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-06-30 0000310158 mrk:EisaiMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-06-30 0000310158 mrk:EisaiMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2018-04-01 2018-06-30 0000310158 mrk:EisaiMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2019-06-30 0000310158 mrk:EisaiMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2018-04-01 2018-06-30 0000310158 mrk:EisaiMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2018-12-31 0000310158 mrk:EisaiMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-06-30 0000310158 mrk:EisaiMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2018-04-01 2018-06-30 0000310158 mrk:EisaiMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2019-04-01 2019-06-30 0000310158 mrk:EisaiMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-06-30 0000310158 mrk:EisaiMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-06-30 0000310158 mrk:EisaiMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2019-04-01 2019-06-30 0000310158 mrk:EisaiMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-06-30 0000310158 mrk:EisaiMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2018-12-31 0000310158 srt:ScenarioForecastMember 2019-12-31 0000310158 srt:MinimumMember 2019-06-30 0000310158 srt:MaximumMember 2019-06-30 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2019-04-01 2019-06-30 0000310158 us-gaap:OtherRestructuringMember 2019-01-01 2019-06-30 0000310158 us-gaap:RestructuringChargesMember 2019-04-01 2019-06-30 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2019-01-01 2019-06-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember 2019-04-01 2019-06-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OneTimeTerminationBenefitsMember 2019-01-01 2019-06-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember 2019-01-01 2019-06-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember 2019-01-01 2019-06-30 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2019-04-01 2019-06-30 0000310158 us-gaap:RestructuringChargesMember 2019-01-01 2019-06-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OneTimeTerminationBenefitsMember 2019-04-01 2019-06-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OneTimeTerminationBenefitsMember 2019-01-01 2019-06-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember 2019-04-01 2019-06-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OneTimeTerminationBenefitsMember 2019-04-01 2019-06-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember 2019-01-01 2019-06-30 0000310158 us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember 2019-04-01 2019-06-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2019-01-01 2019-06-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember 2019-04-01 2019-06-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:AcceleratedDepreciationMember 2019-04-01 2019-06-30 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2019-01-01 2019-06-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OneTimeTerminationBenefitsMember 2019-04-01 2019-06-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0000310158 mrk:AcceleratedDepreciationMember 2019-04-01 2019-06-30 0000310158 us-gaap:OtherRestructuringMember 2019-04-01 2019-06-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-04-01 2019-06-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-06-30 0000310158 us-gaap:CostOfSalesMember 2019-01-01 2019-06-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2019-04-01 2019-06-30 0000310158 us-gaap:CostOfSalesMember us-gaap:OneTimeTerminationBenefitsMember 2019-04-01 2019-06-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:AcceleratedDepreciationMember 2019-01-01 2019-06-30 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember 2019-01-01 2019-06-30 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember 2019-04-01 2019-06-30 0000310158 us-gaap:CostOfSalesMember us-gaap:OneTimeTerminationBenefitsMember 2019-01-01 2019-06-30 0000310158 mrk:AcceleratedDepreciationMember 2019-01-01 2019-06-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember 2019-01-01 2019-06-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OneTimeTerminationBenefitsMember 2019-01-01 2019-06-30 0000310158 mrk:AcceleratedDepreciationMember 2019-06-30 0000310158 mrk:AcceleratedDepreciationMember 2018-12-31 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2018-12-31 0000310158 us-gaap:OtherRestructuringMember 2018-12-31 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2019-06-30 0000310158 us-gaap:OtherRestructuringMember 2019-06-30 0000310158 mrk:AcceleratedDepreciationMember 2018-04-01 2018-06-30 0000310158 us-gaap:RestructuringChargesMember 2018-01-01 2018-06-30 0000310158 us-gaap:OtherRestructuringMember 2018-01-01 2018-06-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OneTimeTerminationBenefitsMember 2018-04-01 2018-06-30 0000310158 us-gaap:CostOfSalesMember 2018-01-01 2018-06-30 0000310158 us-gaap:CostOfSalesMember 2018-04-01 2018-06-30 0000310158 mrk:AcceleratedDepreciationMember 2018-01-01 2018-06-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember 2018-04-01 2018-06-30 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2018-01-01 2018-06-30 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember 2018-01-01 2018-06-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OneTimeTerminationBenefitsMember 2018-04-01 2018-06-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-06-30 0000310158 us-gaap:CostOfSalesMember us-gaap:OneTimeTerminationBenefitsMember 2018-04-01 2018-06-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-04-01 2018-06-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember 2018-04-01 2018-06-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-06-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2018-04-01 2018-06-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OneTimeTerminationBenefitsMember 2018-04-01 2018-06-30 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember 2018-01-01 2018-06-30 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember 2018-04-01 2018-06-30 0000310158 us-gaap:RestructuringChargesMember 2018-04-01 2018-06-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember 2018-01-01 2018-06-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-01 2018-06-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:AcceleratedDepreciationMember 2018-04-01 2018-06-30 0000310158 us-gaap:CostOfSalesMember us-gaap:OneTimeTerminationBenefitsMember 2018-01-01 2018-06-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember 2018-04-01 2018-06-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OneTimeTerminationBenefitsMember 2018-01-01 2018-06-30 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember 2018-04-01 2018-06-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OneTimeTerminationBenefitsMember 2018-01-01 2018-06-30 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2018-04-01 2018-06-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2018-01-01 2018-06-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:AcceleratedDepreciationMember 2018-01-01 2018-06-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember 2018-01-01 2018-06-30 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2018-01-01 2018-06-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OneTimeTerminationBenefitsMember 2018-01-01 2018-06-30 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2018-04-01 2018-06-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember 2018-01-01 2018-06-30 0000310158 us-gaap:OtherRestructuringMember 2018-04-01 2018-06-30 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2018-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2018-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-06-30 0000310158 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-06-30 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-06-30 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-06-30 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesMember 2018-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-06-30 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-06-30 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-06-30 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-06-30 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-06-30 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-06-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2018-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-06-30 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-06-30 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-06-30 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-06-30 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesMember 2018-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2018-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesMember 2019-06-30 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-06-30 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesMember 2019-06-30 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-06-30 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesMember 2019-06-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-06-30 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-06-30 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesMember 2018-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesMember 2018-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-06-30 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesMember 2019-06-30 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-06-30 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000310158 us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember 2019-06-30 0000310158 us-gaap:MortgageBackedSecuritiesMember 2019-06-30 0000310158 us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000310158 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0000310158 us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-06-30 0000310158 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-06-30 0000310158 us-gaap:AssetBackedSecuritiesMember 2019-06-30 0000310158 us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000310158 us-gaap:MortgageBackedSecuritiesMember 2018-12-31 0000310158 srt:MaximumMember us-gaap:NondesignatedMember 2019-01-01 2019-06-30 0000310158 us-gaap:FairValueInputsLevel2Member 2019-06-30 0000310158 mrk:GefapixantMember 2018-01-01 2018-06-30 0000310158 srt:MaximumMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-06-30 0000310158 us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-06-30 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-06-30 0000310158 us-gaap:AssetBackedSecuritiesMember 2019-01-01 2019-06-30 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-04-01 2019-06-30 0000310158 us-gaap:ForeignExchangeContractMember 2018-04-01 2018-06-30 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-06-30 0000310158 us-gaap:InterestRateSwapMember 2018-04-01 2018-06-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2018-04-01 2018-06-30 0000310158 us-gaap:InterestRateSwapMember 2018-01-01 2018-06-30 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-04-01 2018-06-30 0000310158 us-gaap:ForeignExchangeContractMember 2019-01-01 2019-06-30 0000310158 us-gaap:InterestRateSwapMember 2019-04-01 2019-06-30 0000310158 us-gaap:InterestRateSwapMember 2019-01-01 2019-06-30 0000310158 us-gaap:ForeignExchangeContractMember 2019-04-01 2019-06-30 0000310158 us-gaap:ForeignExchangeContractMember 2018-01-01 2018-06-30 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-06-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-04-01 2019-06-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2018-01-01 2018-06-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-01-01 2019-06-30 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000310158 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000310158 us-gaap:NondesignatedMember 2019-06-30 0000310158 us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-06-30 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-06-30 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2018-12-31 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2018-12-31 0000310158 us-gaap:NondesignatedMember 2018-12-31 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000310158 us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000310158 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000310158 us-gaap:OtherAssetsMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000310158 us-gaap:OtherAssetsMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000310158 mrk:LongTermDebtCurrentMaturitiesMember 2018-12-31 0000310158 mrk:LongTermDebtExcludingCurrentMaturitiesMember 2019-06-30 0000310158 mrk:LongTermDebtExcludingCurrentMaturitiesMember 2018-12-31 0000310158 mrk:LongTermDebtCurrentMaturitiesMember 2019-06-30 0000310158 us-gaap:CurrencySwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-06-30 0000310158 us-gaap:CurrencySwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-04-01 2019-06-30 0000310158 us-gaap:CurrencySwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-04-01 2018-06-30 0000310158 us-gaap:ForeignExchangeFutureMember us-gaap:SalesMember 2018-04-01 2018-06-30 0000310158 us-gaap:ForeignExchangeFutureMember us-gaap:SalesMember 2019-01-01 2019-06-30 0000310158 us-gaap:ForeignExchangeFutureMember us-gaap:SalesMember 2019-04-01 2019-06-30 0000310158 us-gaap:ForeignExchangeFutureMember us-gaap:SalesMember 2018-01-01 2018-06-30 0000310158 us-gaap:CurrencySwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-06-30 0000310158 us-gaap:InterestRateSwapMember mrk:A3.875NotesDue2021Member 2019-06-30 0000310158 us-gaap:InterestRateSwapMember mrk:A2.35NotesDue2022Member 2019-06-30 0000310158 us-gaap:InterestRateSwapMember mrk:A1.85NotesDue2020Member 2019-06-30 0000310158 us-gaap:InterestRateSwapMember mrk:A2.40NotesDue2022Member 2019-06-30 0000310158 mrk:EurodominatedNotesMember 2019-04-01 2019-06-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-04-01 2018-06-30 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-06-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-06-30 0000310158 mrk:EurodominatedNotesMember 2018-04-01 2018-06-30 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-04-01 2019-06-30 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-06-30 0000310158 mrk:EurodominatedNotesMember 2018-01-01 2018-06-30 0000310158 mrk:EurodominatedNotesMember 2019-01-01 2019-06-30 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-04-01 2018-06-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-06-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-04-01 2019-06-30 0000310158 mrk:InventoriesProducedinPreparationforProductLaunchesMember 2018-12-31 0000310158 mrk:InventoriesProducedinPreparationforProductLaunchesMember 2019-06-30 0000310158 mrk:InventoryNotExpectedtobeSoldWithinOneYearMember 2018-12-31 0000310158 mrk:InventoryNotExpectedtobeSoldWithinOneYearMember 2019-06-30 0000310158 us-gaap:BuildingMember 2019-06-30 0000310158 us-gaap:SubsequentEventMember 2019-07-31 0000310158 us-gaap:VehiclesMember 2019-06-30 0000310158 mrk:A4.00NotesDue2049Member 2019-03-31 0000310158 mrk:A3.40NotesDue2029Member 2019-03-31 0000310158 mrk:A3.90NotesDue2039Member 2019-03-31 0000310158 2019-03-31 0000310158 2019-03-01 2019-03-31 0000310158 mrk:A2.90NotesDue2024Member 2019-03-31 0000310158 mrk:NewJerseyMember mrk:FosamaxMember mrk:FemurFractureLitigationMember 2019-06-30 0000310158 mrk:LegalDefenseCostsMember 2018-12-31 0000310158 mrk:FederalMember mrk:FosamaxMember mrk:FemurFractureLitigationMember 2014-03-01 2014-03-31 0000310158 mrk:FederalMember mrk:FosamaxMember mrk:FemurFractureLitigationMember 2019-01-01 2019-06-30 0000310158 mrk:JanuviaMember mrk:CasesCompanyAgreedToTollStatuteOfLimitationsMember 2019-06-30 0000310158 mrk:OtherStateCourtMember mrk:FosamaxMember mrk:FemurFractureLitigationMember 2019-06-30 0000310158 mrk:OtherStateCourtMember mrk:JanuviaMember 2019-06-30 0000310158 mrk:CaliforniaStateCourtMember mrk:FosamaxMember mrk:FemurFractureLitigationMember 2019-06-30 0000310158 mrk:FosamaxMember 2019-06-30 0000310158 mrk:JanuviaMember 2019-06-30 0000310158 mrk:LegalDefenseCostsMember 2019-06-30 0000310158 mrk:FederalMember mrk:FosamaxMember mrk:FemurFractureLitigationMember 2019-06-30 0000310158 mrk:AcceleratedShareRepurchaseAgreementMember 2019-04-01 2019-04-30 0000310158 mrk:AcceleratedShareRepurchaseAgreementMember 2018-10-29 2018-10-29 0000310158 mrk:AcceleratedShareRepurchaseAgreementMember 2018-10-29 0000310158 mrk:AcceleratedShareRepurchaseAgreementMember 2018-10-25 0000310158 mrk:AcceleratedShareRepurchaseAgreementMember 2018-10-01 2019-06-30 0000310158 us-gaap:TreasuryStockMember 2018-01-01 2018-06-30 0000310158 us-gaap:RetainedEarningsMember 2018-01-01 2018-06-30 0000310158 us-gaap:TreasuryStockMember 2017-12-31 0000310158 us-gaap:CommonStockMember 2017-12-31 0000310158 us-gaap:RetainedEarningsMember 2018-06-30 0000310158 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000310158 us-gaap:TreasuryStockMember 2019-01-01 2019-06-30 0000310158 us-gaap:CommonStockMember 2019-06-30 0000310158 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0000310158 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0000310158 us-gaap:RetainedEarningsMember 2017-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000310158 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-06-30 0000310158 2018-01-01 0000310158 us-gaap:TreasuryStockMember 2019-06-30 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-06-30 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000310158 us-gaap:RetainedEarningsMember 2018-12-31 0000310158 us-gaap:CommonStockMember 2018-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 0000310158 us-gaap:TreasuryStockMember 2018-12-31 0000310158 us-gaap:RetainedEarningsMember 2019-06-30 0000310158 us-gaap:NoncontrollingInterestMember 2017-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-06-30 0000310158 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-06-30 0000310158 us-gaap:RetainedEarningsMember 2018-01-01 0000310158 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-06-30 0000310158 us-gaap:TreasuryStockMember 2018-06-30 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000310158 us-gaap:CommonStockMember 2018-06-30 0000310158 us-gaap:NoncontrollingInterestMember 2018-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2019-06-30 0000310158 us-gaap:NoncontrollingInterestMember 2018-06-30 0000310158 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000310158 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000310158 us-gaap:CommonStockMember 2019-03-31 0000310158 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0000310158 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000310158 us-gaap:TreasuryStockMember 2018-04-01 2018-06-30 0000310158 us-gaap:RetainedEarningsMember 2018-03-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0000310158 us-gaap:CommonStockMember 2018-03-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000310158 us-gaap:NoncontrollingInterestMember 2019-04-01 2019-06-30 0000310158 us-gaap:TreasuryStockMember 2019-03-31 0000310158 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0000310158 us-gaap:NoncontrollingInterestMember 2018-03-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0000310158 2018-03-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000310158 us-gaap:NoncontrollingInterestMember 2018-04-01 2018-06-30 0000310158 us-gaap:NoncontrollingInterestMember 2019-03-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000310158 us-gaap:TreasuryStockMember 2018-03-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0000310158 us-gaap:RetainedEarningsMember 2019-03-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000310158 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-06-30 0000310158 us-gaap:PerformanceSharesMember 2018-01-01 2018-06-30 0000310158 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0000310158 us-gaap:PerformanceSharesMember 2019-01-01 2019-06-30 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-04-01 2019-06-30 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-04-01 2019-06-30 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2018-01-01 2018-06-30 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2018-01-01 2018-06-30 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2018-04-01 2018-06-30 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2018-04-01 2018-06-30 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-06-30 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-06-30 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-04-01 2018-06-30 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-01-01 2018-06-30 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-04-01 2019-06-30 0000310158 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2019-01-01 2019-03-31 0000310158 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2019-01-01 2019-06-30 0000310158 mrk:EisaiMember 2018-01-01 2018-06-30 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-06-30 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-06-30 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-01-01 2018-06-30 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-06-30 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2017-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-06-30 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-06-30 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2019-06-30 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2018-06-30 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-06-30 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-06-30 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-06-30 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-01-01 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-06-30 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-04-01 2019-06-30 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-04-01 2018-06-30 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-04-01 2019-06-30 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-03-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-03-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-04-01 2018-06-30 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-03-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-03-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-03-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-03-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2018-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:CorporateNonSegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember country:US us-gaap:AllOtherSegmentsMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 country:US 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 mrk:InternationalMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember country:US us-gaap:AllOtherSegmentsMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember us-gaap:AllOtherSegmentsMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 mrk:InternationalMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember us-gaap:AllOtherSegmentsMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 country:US 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember country:US us-gaap:AllOtherSegmentsMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 country:US 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember us-gaap:AllOtherSegmentsMember 2018-04-01 2018-06-30 0000310158 us-gaap:CorporateNonSegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:CorporateNonSegmentMember country:US 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember country:US 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember country:US 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember country:US 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember country:US 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 mrk:InternationalMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 mrk:InternationalMember 2019-01-01 2019-06-30 0000310158 us-gaap:CorporateNonSegmentMember country:US 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 country:US 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2018-01-01 2018-06-30 0000310158 us-gaap:CorporateNonSegmentMember country:US 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember country:US us-gaap:AllOtherSegmentsMember 2019-04-01 2019-06-30 0000310158 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember us-gaap:AllOtherSegmentsMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:CorporateNonSegmentMember country:US 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember country:US mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:PharmaceuticalsegmentMember 2019-04-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2018-04-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2018-01-01 2018-06-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-06-30 0000310158 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-06-30 0000310158 us-gaap:MaterialReconcilingItemsMember 2018-01-01 2018-06-30 0000310158 us-gaap:MaterialReconcilingItemsMember 2018-04-01 2018-06-30 0000310158 us-gaap:MaterialReconcilingItemsMember 2019-04-01 2019-06-30 0000310158 country:JP 2018-04-01 2018-06-30 0000310158 srt:AsiaPacificMember 2019-04-01 2019-06-30 0000310158 srt:AsiaPacificMember 2019-01-01 2019-06-30 0000310158 us-gaap:EMEAMember 2018-04-01 2018-06-30 0000310158 srt:LatinAmericaMember 2019-04-01 2019-06-30 0000310158 country:JP 2018-01-01 2018-06-30 0000310158 mrk:OtherCountriesMember 2019-01-01 2019-06-30 0000310158 us-gaap:EMEAMember 2018-01-01 2018-06-30 0000310158 srt:LatinAmericaMember 2018-04-01 2018-06-30 0000310158 srt:AsiaPacificMember 2018-01-01 2018-06-30 0000310158 country:CN 2019-01-01 2019-06-30 0000310158 us-gaap:EMEAMember 2019-01-01 2019-06-30 0000310158 country:CN 2019-04-01 2019-06-30 0000310158 country:CN 2018-01-01 2018-06-30 0000310158 mrk:OtherCountriesMember 2019-04-01 2019-06-30 0000310158 srt:LatinAmericaMember 2018-01-01 2018-06-30 0000310158 mrk:OtherCountriesMember 2018-04-01 2018-06-30 0000310158 srt:LatinAmericaMember 2019-01-01 2019-06-30 0000310158 country:JP 2019-01-01 2019-06-30 0000310158 mrk:OtherCountriesMember 2018-01-01 2018-06-30 0000310158 srt:AsiaPacificMember 2018-04-01 2018-06-30 0000310158 country:JP 2019-04-01 2019-06-30 0000310158 us-gaap:EMEAMember 2019-04-01 2019-06-30 0000310158 country:CN 2018-04-01 2018-06-30 xbrli:pure iso4217:USD xbrli:shares xbrli:shares iso4217:AUD mrk:interest_rate_swap iso4217:USD mrk:Claim mrk:Case mrk:segment



 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
 
 
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2019
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to ______
Commission File No. 1-6571
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey
22-1918501
(State or other jurisdiction of incorporation)
(I.R.S Employer Identification No.)
 
 
2000 Galloping Hill Road
Kenilworth
New Jersey
07033
(Address of principal executive offices) (zip code)
(Registrant’s telephone number, including area code) (908) 740-4000
 
Not Applicable
 
(Former name, former address and former fiscal year, if changed since last report.)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes     No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes     No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
Accelerated filer
 
 
 
 
Non-accelerated filer
Smaller reporting company
 
 
 
 
 
 
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes   No 
Securities Registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock ($0.50 par value)
MRK
New York Stock Exchange
1.125% Notes due 2021
MRK/21
New York Stock Exchange
0.500% Notes due 2024
MRK 24
New York Stock Exchange
1.875% Notes due 2026
MRK/26
New York Stock Exchange
2.500% Notes due 2034
MRK/34
New York Stock Exchange
1.375% Notes due 2036
MRK 36A
New York Stock Exchange
The number of shares of common stock outstanding as of the close of business on July 31, 2019: 2,560,374,643
 





Part I - Financial Information
Item 1. Financial Statements
MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF INCOME
(Unaudited, $ in millions except per share amounts)
 
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2019
 
2018
 
2019
 
2018
Sales
$
11,760

 
$
10,465

 
$
22,575

 
$
20,502

Costs, Expenses and Other
 
 
 
 
 
 
 
Cost of sales
3,401

 
3,417

 
6,453

 
6,601

Selling, general and administrative
2,712

 
2,508

 
5,138

 
5,016

Research and development
2,189

 
2,274

 
4,119

 
5,470

Restructuring costs
59

 
228

 
212

 
323

Other (income) expense, net
140

 
(48
)
 
327

 
(340
)
 
8,501

 
8,379

 
16,249

 
17,070

Income Before Taxes
3,259

 
2,086

 
6,326

 
3,432

Taxes on Income
615

 
370

 
820

 
975

Net Income
2,644

 
1,716

 
5,506

 
2,457

Less: Net (Loss) Income Attributable to Noncontrolling Interests
(26
)
 
9

 
(79
)
 
14

Net Income Attributable to Merck & Co., Inc.
$
2,670

 
$
1,707

 
$
5,585

 
$
2,443

Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders
$
1.04

 
$
0.64

 
$
2.17

 
$
0.91

Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders
$
1.03

 
$
0.63

 
$
2.15

 
$
0.90

 
MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(Unaudited, $ in millions)
 
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2019
 
2018
 
2019
 
2018
Net Income Attributable to Merck & Co., Inc.
$
2,670

 
$
1,707

 
$
5,585

 
$
2,443

Other Comprehensive (Loss) Income Net of Taxes:
 
 
 
 
 
 
 
Net unrealized (loss) gain on derivatives, net of reclassifications
(52
)
 
266

 
(100
)
 
196

Net unrealized gain (loss) on investments, net of reclassifications
44

 
3

 
126

 
(96
)
Benefit plan net gain and prior service credit, net of amortization
11

 
30

 
26

 
66

Cumulative translation adjustment
(19
)
 
(361
)
 
131

 
(104
)
 
(16
)
 
(62
)
 
183

 
62

Comprehensive Income Attributable to Merck & Co., Inc.
$
2,654

 
$
1,645

 
$
5,768

 
$
2,505

 The accompanying notes are an integral part of these condensed consolidated financial statements.

- 2 -




MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEET
(Unaudited, $ in millions except per share amounts)
 
 
June 30, 2019
 
December 31, 2018
Assets
 
 
 
Current Assets
 
 
 
Cash and cash equivalents
$
6,659

 
$
7,965

Short-term investments
446

 
899

Accounts receivable (net of allowance for doubtful accounts of $122 in 2019
and $119 in 2018)
7,964

 
7,071

Inventories (excludes inventories of $1,464 in 2019 and $1,417 in 2018
classified in Other assets - see Note 6)
5,847

 
5,440

Other current assets
3,382

 
4,500

Total current assets
24,298

 
25,875

Investments
3,779

 
6,233

Property, Plant and Equipment, at cost, net of accumulated depreciation of $17,049
in 2019 and $16,324 in 2018
13,862

 
13,291

Goodwill
19,490

 
18,253

Other Intangibles, Net
13,381

 
11,431

Other Assets
9,155

 
7,554

 
$
83,965

 
$
82,637

Liabilities and Equity
 
 
 
Current Liabilities
 
 
 
Loans payable and current portion of long-term debt
$
3,816

 
$
5,308